Company Overview - Monopar Therapeutics Inc. (NASDAQ: MNPR) has initiated dosing of its first patient with the radiotherapeutic candidate MNPR-101-Lu aimed at treating advanced solid tumors [4] Unique Selling Proposition - The radiotherapeutic candidate MNPR-101-Lu is highlighted as a unique offering in the market, although specific differentiating factors are not detailed in the provided content [4]

Company Overview - Monopar Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs [4][11] - The company is working on late-stage ALXN-1840 for Wilson disease and has several radiopharmaceutical programs in various stages of development [11] Offering Details - Monopar announced the pricing of an underwritten registered offering of 798,655 shares of its common stock at an offering price of $23.79 per share [4] - Additionally, a private placement of pre-funded warrants to purchase 882,761 shares of common stock was priced at $23.789 per warrant [4] - The gross proceeds from both the registered offering and private placement are expected to be $40 million before deducting underwriting discounts and commissions [4][9] - The offering is expected to close on or about December 23, 2024, subject to customary closing conditions [4] Use of Proceeds - The net proceeds from the offering are intended for general corporate purposes, which may include research and development expenditures, clinical trial expenditures, manufacture and supply of product, and working capital [9] Management and Underwriters - Piper Sandler & Co. is acting as the sole book-running manager for the offering [5]

WILMETTE, Ill., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the first patient ever dosed with MNPR-101-Lu. This novel therapeutic radiopharmaceutical combines MNPR-101, Monopar’s antibody that selectively targets the urokinase plasminogen activator receptor (uPAR), with the therapeutic radioisotope lutetium-177. uPAR is involved in tumor gr ...

WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will participate in a fireside chat along with one-on-one meetings at the 36th Annual Piper Sandler Healthcare Conference. Presentation Details: Date: December 5, 2024Time: 10:30-10:55 am Eastern Time Location: Lotte Ne ...

Investors favoring a short horizon and possessing a fair amount of risk tolerance sometimes look to stocks that have already been trending upward in an effort to capitalize on their momentum. This investment strategy often looks more toward price movement than it does the fundamentals of a company. However, some investors feel most secure in a momentum investment when they believe the firm's business is solid as well. The S&P 500 has rallied considerably in the last year, rising by 32.3% in the 12 months th ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.Our " ...

Monopar Therapeutics Inc. (NASDAQ: MNPR ) develops radiopharmaceutical solutions to address the unmet medical needs of cancer patients and, more recently, rare diseases. MNPR integrates radiodiagnostics and radiotherapeutics to visualize and kill cancer cells. MNPR has MNPR-101-Zr, an imaging agent. Similarly, MNPR-101-Lu and MNPR-101-Ac are radiation-basedMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ec ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091 (Address of principal executive offices) (Zip Code) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value MNPRThe Nasdaq Stock Market LLC (Nasdaq Capital Market) FORM 8-K CURRENT REPORT Pursuant ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2024 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39070 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) | --- | --- | |------ ...

In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid Cancers WILMETTE, Ill., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced third quarter 2024 financial results and summari ...